Current best practice in the management of hypertensive disorders in pregnancy

Integrated Blood Pressure Control

Volumn 9, Issue , 2016, Pages 79-94

  Townsend, Rosemary ^a   O’Brien, Patrick ^b   Khalil, Asma ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Blood pressure; Eclampsia; Gestational hypertension; Management; Outcome; Preeclampsia; Pregnancy screening; Treatment

Indexed keywords

ATENOLOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HOMOCYSTEINE; HYDRALAZINE; LABETALOL; LEPTIN; METHYLDOPA; N(G),N(G) DIMETHYLARGININE; NIFEDIPINE; PLACENTA PROTEIN; PLACENTA PROTEIN 13; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; URIC ACID;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ECLAMPSIA; FEMALE; FETUS MONITORING; HELLP SYNDROME; HUMAN; INTRAPARTUM CARE; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LUNG EDEMA; MATERNAL CARE; MATERNAL HYPERTENSION; OBSTETRIC DELIVERY; PATIENT EDUCATION; POSTNATAL CARE; POSTPARTUM HYPERTENSION; PREECLAMPSIA; PRENATAL CARE; PREPREGNANCY HYPERTENSION; PROTEINURIA; REVIEW; RISK ASSESSMENT; TIME TO TREATMENT;

EID: 84992410728     PISSN: None     EISSN: 11787104     Source Type: Journal    
DOI: 10.2147/IBPC.S77344     Document Type: Review

References (60)

1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009; 33 (3): 130–137.
2. World Health Organisation. The World Health Report 2005: Make Every Mother and Child Count. Geneva, Switzerland: World Health Organization; 2005.
3. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010; 376 (9741): 631–644.
4. Cantwell R, Clutton-Brock T, Cooper G, et al. Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood safer: 2006–2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG. 2011; 118 (Suppl 1): 1–203.
5. Verghese L, Alam S, Beski S, Thuraisingham R, Barnes I, MacCallum P. Antenatal screening for pre-eclampsia: evaluation of the NICE and pre-eclampsia community guidelines. J Obstet Gynaecol. 2012; 32 (2): 128–131.
6. Redman CW. Current topic: pre-eclampsia and the placenta. Placenta. 1991; 12 (4): 301–308.
7. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 1993; 341 (8858): 1447–1451.
8. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension. 2001; 38 (3 Pt 2): 718–722.
9. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ. 2001; 323 (7323): 1213–1217.
10. Smith GC, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129, 290 births. Lancet. 2001; 357 (9273): 2002–2006.
11. Ray JG, Vermeulen MJ, Schull MJ, Redelmeier DA. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005; 366 (9499): 1797–1803.
12. Bellamy L, Casas J-P, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ. 2007; 335 (7627): 974.
13. Wu CS, Nohr EA, Bech BH, Vestergaard M, Catov JM, Olsen J. Health of children born to mothers who had preeclampsia: a population-based cohort study. Am J Obstet Gynecol. 2009; 201 (3): 269.e1–269.e10.
14. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy Obstet Gynecol. 2013; 122 (5): 1122–1131.
15. Tranquilli AL, Dekker G, Magee L, et al. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. Pregnancy Hypertens. 2014; 4 (2): 97–104.
16. Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ. 2014; 348: g2301.
17. Chappell LC, Enye S, Seed P, Briley AL, Poston L, Shennan AH. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension. 2008; 51: 1002–1009.
18. National Collaborating Centre for Women’s and Children’s Health (UK). Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. London, UK: RCOG Press; 2010.
19. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P; Hypertension Guideline Committee. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary J Obstet Gynaecol Can. 2014; 36 (5): 416–441.
20. Department of Reproductive Health, Department of Maternal, Newborn, Child and Adolescent Healt, Department of Nutrition for Health and Development, World Health Organization. WHO Recommendations for Prevention and Treatment of Pre-eclampsia and Eclampsia. Geneva, Switzerland: World Health Organization; 2011.
21. Waugh JJS, Gupta M, Rushbrook J, Halligan A, Shennan AH. Hidden errors of aneroid sphygmomanometers. Blood Press Monit. 2002; 7 (6): 309–312.
22. Petrie JC, O’Brien ET, Littler WA, de Swiet M. Recommendations on blood pressure measurement. Br Med J (Clin Res Ed). 1986; 293 (6547): 611–615.
23. Chappell LC, Shennan AH. Assessment of proteinuria in pregnancy. BMJ. 2008; 336: 968–969.
24. Morikawa M, Yamada T, Yamada T, et al. Pregnancy outcome of women who developed proteinuria in the absence of hypertension after mid-gestation. J Perinat Med. 2008; 35 (5): 419–424.
25. Brown MA, Mangos G, Davis G, Homer C. The natural history of white coat hypertension during pregnancy. BJOG. 2005; 112 (5): 601–606.
26. Knight M. Eclampsia in the United Kingdom 2005. BJOG. 2007; 114: 1072–1078.
27. Lindheimer MD, Taler SJ, Cunningham FG. Hypertension in pregnancy. J Am Soc Hypertens. 2008; 2: 484–494.
28. Thangaratinam S, Coomarasamy A, O’Mahony F, et al. Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review. BMC Med. 2009; 7 (1): 10.
29. Sibai BM, Ramadan MK, Usta I, Salama M, Mercer BM, Friedman SA. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol. 1993; 169 (4): 1000–1006.
30. Haddad B, Barton JR, Livingston JC, Chahine R, Sibai BM. HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome versus severe preeclampsia: onset at 28.0 weeks’ gestation. Am J Obstet Gynecol. 2000; 183 (6): 1475–1479.
31. Malvino E, Mu�oz M, Ceccotti C, et al. Maternal morbidity and perinatal mortality in HELLP syndrome. Multicentric studies in intensive care units in Buenos Aires area. Medicina (B Aires). 2005; 65 (1): 17–23. Spanish.
32. Larsson A, Palm M, Hansson L-O, Axelsson O. Reference values for clinical chemistry tests during normal pregnancy. BJOG. 2008; 115 (7): 874–881.
33. Greer IA. Maternal Medicine: Medical Problems in Pregnancy. Philadelphia, PA: Elsevier Health Sciences; 2007.
34. Wagner SJ, Acquah LA, Lindell EP, et al. Posterior reversible encephalopathy syndrome and eclampsia: pressing the case for more aggressive blood pressure control. Mayo Clin Proc. 2011; 86 (9): 851–856.
35. Sibai BM. Imitators of severe pre-eclampsia/eclampsia. Clin Perinatol. 2004; 31 (4): 835–852.
36. Poon LC, Nicolaides KH. Early prediction of preeclampsia. Obstet Gynecol Int. 2014; 2014: 297397.
37. Akolekar R, Zaragoza E, Poon LC, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol. 2008; 32 (6): 732–739.
38. Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for. J Matern Fetal Neonatal Med. 2008; 21 (1): 9–23.
39. Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010; 202 (2): 161.e1–161.e11.
40. Engels T, Pape J, Schoofs K, Henrich W, Verlohren S. Automated measurement of sFlt1, PlGF and sFlt1/PlGF ratio in differential diagnosis of hypertensive pregnancy disorders. Hypertens Pregnancy. 2013; 32 (4): 459–473.
41. Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 2010; 116 (2 Pt 1): 402–414.
42. Villa PM, Kajantie E, R�ikk�nen K, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials. BJOG. 2013; 120 (1): 64–74.
43. Thangaratinam S, Langenveld J, Mol BW, Khan KS. Prediction and primary prevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011; 25 (4): 419–433.
44. Villar J, Abdel-Aleem H, Merialdi M, et al. World Health Organization randomized trial of calcium supplementation among low calcium intake pregnant women. Am J Obstet Gynecol. 2006; 194 (3): 639–649.
45. Poon LC, Nicolaides KH. First-trimester maternal factors and biomarker screening for preeclampsia. Prenat Diagn. 2014; 34 (7): 618–627.
46. Milne F, Redman C, Walker J, et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ. 2005; 330 (7491): 576–580.
47. Thangaratinam S, Ismail KMK, Sharp S, Coomarasamy A, Khan KS. Accuracy of serum uric acid in predicting complications of pre-eclampsia: A systematic review. BJOG. 2006; 113 (4): 369–378.
48. Meher S, Abalos E, Carroli G. Bed rest with or without hospitalisation for hypertension during pregnancy. Cochrane Database Syst Rev. 2005; 4: CD003514.
49. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013; 7: CD001449.
50. Brown MJ. Renin: friend or foe? Heart. 2007; 93: 1026–1033.
51. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003; 327 (7421): 955–960.
52. Churchill D, Duley L, Thornton JG, Jones L. Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation. Cochrane Database Syst Rev. 2013; 7: CD003106.
53. The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet. 2002; 359 (9321): 1877–1890.
54. The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet. 1995; 345 (8963): 1455–1463.
55. Von Dadelszen P, Payne B, Li J, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet. 2011; 377: 219–227.
56. Akkermans J, Payne B, von Dadelszen P, et al. Predicting complications in pre-eclampsia: external validation of the fullPIERS model using the PETRA trial dataset. Eur J Obstet Gynecol Reprod Biol. 2014; 179: 58–62.
57. Payne B, Hutcheon JA, Ansermino JM, et al. A risk prediction model for the assessment and triage of women with hypertensive disorders of pregnancy in low-resourced settings: the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country prospective cohort study. PLoS Med. 2014; 11 (1): e1001589. doi: 10.1371/journal.pmed.1001589.
58. Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009; 374 (9694): 979–988.
59. Bramham K, Nelson-Piercy C, Brown MJ, Chappell LC. Postpartum management of hypertension. BMJ. 2013; 346: f894.
60. Berks D, Steegers EAP, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. Obstet Gynecol. 2009; 114: 1307–1314.